The U.S. Food and Drug Administration (FDA) has given Lion TCR the green light to start Phase 1b/2 clinical trials testing LioCyx-M004, the clinical-stage biotechnology company’s experimental cell therapy for chronic hepatitis B. The FDA clearance to launch the trials follows the agency’s granting of both fast track and orphan drug designations to the treatment […] The post FDA OKs clinical trials to test cell therapy for chronic hepatitis B appeared first on Liver Disease News.
